130 patents
Utility
Triaryl Compounds for Treatment of PD-L1 Diseases
9 Feb 23
Pingchen FAN, Christopher LANGE, Venkat Reddy MALI, Darren J. McMURTRIE, Viengkham MALATHONG, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Yibin ZENG, Penglie ZHANG
Filed: 14 Jan 22
Utility
Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1/PD-L1 Inhibitor
26 Jan 23
The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
James J. CAMPBELL, Zhenhua MIAO, Thomas J. SCHALL, Israel CHARO, Shijie LI, Christine Marie JANSON, Rajinder SINGH, Karen EBSWORTH
Filed: 15 Mar 22
Utility
PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
12 Jan 23
Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
Pingchen FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Rebecca M. LUI, Jay POWERS, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG
Filed: 8 Feb 22
Utility
Method of Treating C3 Glomerulopathy
10 Nov 22
Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
Petrus BEKKER
Filed: 14 Feb 22
Utility
Azetidinyl-acetamides As CXCR7 Inhibitors
3 Nov 22
Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
Filed: 18 Apr 22
Utility
Compounds for treatment of PD-L1 diseases
1 Nov 22
Viengkham Malathong, Pingchen Fan, Christopher Lange, Venkat Reddy Mali, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Ju Yang, Penglie Zhang
Filed: 19 Jun 20
Utility
Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
1 Nov 22
Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Yibin Zeng, Penglie Zhang
Filed: 27 Jul 20
Utility
5-5 fused rings as C5a inhibitors
25 Oct 22
Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Yibin Zeng, Penglie Zhang
Filed: 4 May 20
Utility
Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
25 Oct 22
Pingchen Fan, Christopher W. Lange, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
Filed: 25 Sep 20
Utility
CXCR7 inhibitors for the treatment of cancer
11 Oct 22
Provided herein are methods of treating cancer in an individual in need thereof, the methods comprising administering to the individual a CXCR7 inhibitor.
Noriko Gotoh, James J. Campbell
Filed: 11 Dec 19
Utility
Method of Treating Liver Fibrosis
6 Oct 22
A method of treating liver fibrosis with CCR2 antagonists is provided.
Zhenhua MIAO, Israel Charo
Filed: 11 May 22
Utility
DOSING AND EFFECT OF C5a ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS
22 Sep 22
Jun DENG, Petrus BEKKER, Jan HILLSON
Filed: 4 Nov 21
Utility
Treatment of Focal Segmental Glomerulosclerosis with CCR2 Antagonists
22 Sep 22
Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist.
Zhenhua MIAO, Thomas J. Schall, Rajinder Singh
Filed: 3 Jun 22
Utility
Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
20 Sep 22
The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
Shijie Li, Venkat Reddy Mali, Rajinder Singh, Ju Yang, Penglie Zhang
Filed: 28 Aug 19
Utility
Methods of Treating Generalized Pustular Psoriasis with an Antagonist of CCR6 or CXCR2
8 Sep 22
James J. CAMPBELL, Karen EBSWORTH, Antoni KRASINSKI, Venkat Reddy MALI, Jeffrey McMAHON, Rajinder SINGH, Ju YANG, Chao YU, Penglie ZHANG
Filed: 16 Nov 21
Utility
Heteroaryl sulfonamides and CCR2/CCR9
6 Sep 22
Compounds are provided that act as potent antagonists of the CCR2 receptor.
Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor T. Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew M. K. Pennell, John J. Wright, Antoni Krasinski, Qiang Wang
Filed: 10 Jan 20
Utility
2-oxindole compounds
6 Sep 22
Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
Xi Chen, Dean R. Dragoli, Pingchen Fan, Manmohan Reddy Leleti, Rebecca M. Lui, Viengkham Malathong, Jay P. Powers, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
Filed: 17 Jul 20
Utility
Immunomodulator compounds
30 Aug 22
Christopher Lange, Viengkham Malathong, Darren J. McMurtrie, Sreenivas Punna, Rajinder Singh, Ju Yang, Penglie Zhang
Filed: 23 Jan 20
Utility
Salt forms of a complement component C5A receptor
30 Aug 22
Rajinder Singh, Kwok Yau, Yibin Zeng, Penglie Zhang, Rebecca M. Lui, Ju Yang, Howard S. Roth
Filed: 6 Nov 20
Utility
Treatment of C3 Glomerulopathy Using a C5A Inhibitor
18 Aug 22
Methods of treating certain human patient populations suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
Thomas J. SCHALL
Filed: 20 Dec 21